EAElena Altieri

Elena Altieri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Altieri has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stewardship Challenges, PK/PD Evidence, and Prescribing Appropriateness for Recently Approved Antibiotics in Pediatric Practice

    by Alessandra Romandini, Chiara Resnati, Stefania Crucitta, Stefano Agliardi, Federico D’Amico, Giulia Angela Carla Pattarino, Elena Altieri, Romano Danesi, Costantino De Giacomo

    The rise of multidrug-resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling is often deferred due to the complexities of developmental pharmacology and due to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of the most recent antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, and ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting lipoglycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of antimicrobial stewardship through the “3 D’s” rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety controls to proactive, model-informed precision dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.

  • Open Access

    Stewardship Challenges, PK/PD Evidence, and Prescribing Appropriateness of Recently Approved Antibiotics in Pediatric Practice

    by Alessandra Romandini, Chiara Resnati, Stefania Crucitta, Stefano Agliardi, Federico D’Amico, Giulia Carla Angela Pattarino, Elena Altieri, Romano Danesi, Costantino De Giacomo

    The rise of multi-drug resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling often lags due to the complexities of developmental pharmacology and to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of "new" antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting glycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of Antimicrobial Stewardship through the "3 Ds" rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety checks to proactive, Model-Informed Precision Dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.